

# Southeast European MS Congress

## 20-22 May 2022, Belgrade



# PROGRAMME

Friday, 20<sup>th</sup> May 2022

Day 1

Saturday, 21<sup>st</sup> May 2022

Day 2

Sunday, 22<sup>nd</sup> May 2022

Day 3

# 20<sup>th</sup> MAY

## DAY 1 - Friday

	Topic	Lecturer
9.30–10.00	<b>Opening ceremony</b> Chairs: Jelena Drulovic, Tatjana Pekmezovic, Sarlota Mesaros	Jelena Drulovic (SRB) Dragoslav Sokic (SRB) Tatjana Pekmezovic (SRB)
10.00–10.45	Consensus recommendation on the use of MRI in patients with multiple sclerosis	Massimo Filippi (ITA) (online)
10.45–11.30	Treatment of multiple sclerosis in elderly populations	Thomas Berger (AUT) (online)
11.30–12.00	<b>Coffee break</b>	
12.00–12.30	Spinal cord involvement in MS and NMOSD	Maria Assunta Rocca (ITA) (online)
12.30–13.15	<p><b>Satellite Symposium Merck</b></p> <p><b>MAVENCLAD – Are we treating MS patients early enough?</b> Moderator: Jelena Drulovic</p> <p>Early use of Mavenclad in RMS Jelena Drulovic</p> <p>Mavenclad patients from Belgrade registry Sarlota Mesaros</p> <p>Mavenclad patients from Podgorica registry Ljiljana Radulovic</p> <p>Panel discussion and closing remarks – moderator and all presenters</p>	
13.15–14.30	<b>Lunch</b>	
14.30–15.00	Re-examining the role of cytokines and chemokines in MS pathogenesis and therapy	Diego Centonze (ITA)
15.00–15.15	Comorbidity in multiple sclerosis: implications for patients care	Jelena Drulovic (SRB)
15.15–15.30	MS, NMOSD and COVID-19	Sarlota Mesaros (SRB)

# 20<sup>th</sup> MAY

## DAY 1 - Friday

	Topic	Lecturer
15.30–15.45	Long-term efficacy outcomes in patients with highly active relapsing-remitting multiple sclerosis: real-world data from Greece	Nikolaos Grigoriadis (GRC)
15.45–16.00	Use of DMTs during pregnancy and breast feeding	Vanja Basic Kes (HRV)
16.00–16.15	Discussion	
16.15–16.30	<b>Coffee break</b>	
16.30–17.15	<b>Satellite Symposium Novartis</b>  Treatment of Multiple Sclerosis now – efficient and safe Moderator: Jelena Drulovic  Treatment of Relapsing Remitting Multiple Sclerosis - no need for compromise! Sarlota Mesaros  Secondary Progressive Multiple Sclerosis – how to recognise and treat? Slobodan Vojinovic	
17.15–18.00	<b>Satellite Symposium Amicus</b>  Immunomodulatory treatment – need or satisfaction Moderator: Jelena Drulovic  Factors we consider when choosing MS therapy Tatjana Boskovic Matic  Aubagio – efficacy and experience in real word data setting Sarlota Mesaros  Patient satisfaction with Aubagio treatment Slobodan Vojinovic	

# 21<sup>st</sup> MAY

## DAY 2 - Saturday

	Topic	Lecturer
	<b>Chairs:</b> Slobodan Vojinovic, Diego Centonze, Nikolaos Grigoriadis	
10.00–10.15	Real-world data in the assessment of treatment outcomes in multiple sclerosis	Tatjana Pekmezovic (SRB)
10.15–10.30	Immune response to COVID-19 and vaccines in people with multiple sclerosis treated with DMTs	Mario Habek (HRV)
10.30–10.45	The importance of MS registries: our experience from joining MSBase	Magdalena Krbot Skoric (HRV)
10.45–11.00	CSF inflammatory biomarkers in MS	Mario Stampanoni Bassi (ITA)
11.00–11.15	Discussion	
11.15–11.30	<b>Coffee break</b>	
11.30–12.30	<b>Satellite Symposium Hemofarm</b> Creating future led by local evidence Moderator: Jelena Drulovic Participants: Tatjana Pekmezovic Sarlota Mesaros Slobodan Vojinovic Tatjana Boskovic Matic Vesna Suknjaja	
12.30–13.15	<b>Satellite Symposium Medis</b> „RESPONSIBLE to patients - Enhancing clinical care of MS“ Thomas Berger (online) Jelena Drulovic	
13.15–14.30	<b>Lunch</b>	

# 21<sup>st</sup> MAY

## DAY 2 - Saturday

	Topic	Lecturer
	<b>WORKSHOP:</b> Treatment of multiple sclerosis with DMTs in south-east European countries <b>Chairs:</b> Jelena Drulovic, Ivan Milanov, Rodica Ioana Balaşa	
14.30–14.45	Treatment of multiple sclerosis in Serbia	Jelena Drulovic (SRB)
14.45–15.00	Treatment of multiple sclerosis in Bulgaria	Ivan Milanov (BGR)
15.00–15.15	Treatment of multiple sclerosis in Greece	Nikolaos Grigoriadis (GRC)
15.15–15.30	Treatment of multiple sclerosis in Romania	Rodica Ioana Balaşa (ROU)
15.30–15.45	Treatment of multiple sclerosis in Slovenia	Gregor Brecl Jakob (SVN)
15.45–16.00	<b>Coffee break</b>	
16.00–16.15	Treatment of multiple sclerosis in Croatia	Mario Habek (HRV) Vanja Basic Kes (HRV)
16.15–16.30	Treatment of multiple sclerosis in Montenegro	Ljiljana Radulovic (MNE)
16.30–16.45	Treatment of multiple sclerosis in North Macedonia	Ivan Barbov (MKD)
16.45–17.00	Treatment of multiple sclerosis in Bosnia and Herzegovina	Enra Mehmedika Suljic (BIH)
17.00–17.15	Treatment of multiple sclerosis in Republic of Srpska	Sanja Grgic (RS, BIH)
17.15–17.45	Discussion	
17.45–18.15	<b>Satellite Symposium Bayer</b> Betaferon® – proven treatment option for patients with MS 18:00 - 18:15 Long-term experience in treating patients with Betaferon® at Neurology Clinic, Belgrade Jelena Drulovic 18:15 - 18:30 Betaferon treatment during pregnancy and lactation in MS Sarlota Mesaros	
20.00	Gala dinner	

# 22<sup>nd</sup> MAY

## DAY 3 - Sunday

	Topic	Lecturer
	<b>Chairs:</b> Jasna Jancic, Mario Habek, Vanja Basic Kes	
09.30–09.45	Multiple sclerosis in pediatric patients	Jasna Jancic (SRB)
09.45–10.00	Quality of sleep and fatigue in patients with the MS during COVID-19 pandemic	Slobodan Vojinovic (SRB)
10.00–10.15	Association of genetic variants with clinical characteristics in Serbian MS patients	Evica Dincic (SRB)
10.15–10.30	Discussion	
10.30–11.00	<b>Coffee break</b>	
11.00–11.30	<b>Satellite Symposium Roche</b>	
	Neuromyelitis optica spectrum disorder – Importance of accurate diagnosis and early treatment.	
	Moderator: Jelena Drulovic Participants: Jelena Drulovic Sarlota Mesaros Evica Dincic	
11.30–12.00	<b>Satellite Symposium Janssen</b>	
	Treatment of Multiple Sclerosis – Where are we today? Jelena Drulovic	
	S1P1 selective receptormodulation – What can it bring in terms of clinical effectiveness? Slobodan Vojinovic	
	S1P1 selective receptormodulation – What can it bring in terms of clinical safety? Evica Dincic	
	S1P1 selective receptormodulation – Conclusion Jelena Drulovic	
	Discussion	

# 22<sup>nd</sup> MAY

## DAY 3 - Sunday

	Topic	Lecturer
	<b>Chairs:</b> Evica Dincic, Magdalena Krbot Skoric, Gorica Maric	
12.00–12.15	When alemtuzumab fails: what next?	Ivan Adamec (HRV)
12.15–12.30	Complete Freund adjuvant-free EAE: Evaluable tool for MS studies?	Djordje Miljkovic (SRB)
12.30–12.45	COVID-19 in multiple sclerosis treated with interferon beta	Nikola Veselinovic (SRB)
12.45–13.00	Outcomes of COVID-19 in patients with MS treated at the COVID-19 reference hospital in Belgrade	Maja Stefanovic Budimkic (SRB)
13.00–13.15	MS Case report	Nevena Grbic (HRV) (online)
13.15–13.30	MS and NMOSD in two Serbian families	Olivera Tamas (SRB)
13.30–13.45	Malignancies in patients with MS: observational study based on MS Belgrade Registry data	Gorica Maric (SRB)
13.45–14.00	Should D-dimmer increase after alemtuzumab administration be monitored and treated in MS	Jovana Ivanovic (SRB)
14.00–14.15	Discussion	
14.15–14.45	<b>Satellite Symposium Teva</b> Expert insights on heritage, present & future of Copaxone® in MS Panel discussion: Jelena Drulovic Tatjana Pekmezovic Lorand Sakalas <ul style="list-style-type: none"> <li>• Over 20 years of heritage in MS</li> <li>• Enduring clinical value in MS</li> <li>• Family planning in MS</li> <li>• New perspectives and conclusions</li> </ul>	
14.45–15.00	Closing ceremony	
15.00	Lunch	



# Southeast European MS Congress

20-22 May 2022, Belgrade

## Main Sponsor



## Platinum Sponsors



## Gold Sponsors



## Silver Sponsor



## Bronze Sponsors

